Ok so have digested todays announcement a little more and gone back through previous Ann’s:
I can’t help but think it’s an absolute balls up of an announcement. 3-4 Total missed opportunities to announce material news to the market.
Not to mention the wording on the updates, im not even sure these are still correct and given DCB has signed it off i think needs more clarification.
From the Dec22 update - (CCRCC) “Kidney Cancer In H2 CY2022, dose ranging studies of Zantrene and a kinase inhibitor were performed in a rat model of clear cell renal cell carcinoma (kidney cancer). The results of these studies were promising and enable the design of further animal studies exploring the optimal combination and dose of zantrene with kinase inhibitors as a treatment for kidney cancer, updates expected H1 2023
So this was a dose ranging study, and yet its been framed as almost a failure using terminology of not being statistically significant?
From the Dec22 update on MM ”The absence of a well-characterised rodent model of carfilzomib-induced cardiac damage has required the investment of significant time and effort into mouse model development and characterisation. Excellent progress has been made on this project, but an accurate completion timeline cannot be provided at this time”
This was pre-faced as potentially being a challenge, finding a model that may handle it. But saying something failed due to toxicity effects is a poor choice of words when updating the ASX. IMO
Now to the nuts and bolts.
1. Who was ever informed on the below ever initiating, let alone now completing and further “confirming” zantrene’s ability to protect Doxo induced cardiotoxicity…. I mean it’s not like more validation, in the USA, a week after announcing this as a multi billion dollar opportunity would warrant a seperate PS announcement right? Just hide it in the Qtrly - Strike 1 DCB 
2. Nikki’s work completing, which we’re waiting on, where’s the seperate announcement showing the work?? Rather important work dont we think. Strike 2.
And again, another Pre-clinical completed apparently showing increased survival, and yet choose to hide it in the quarterly.
Maybe we are missing Daniel Tillet a little more than we thought we needed to.
